contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

FluoGuide is a Danish company operating in the medical technology sector. The company's business focus is on research and development of treatments for various forms of cancer, with the greatest focus on the development of products that guide surgical procedures. The products bind to cancer cells, which then light up and are intended to be used to precisely remove harmful tumors in the patient's tissue.

FluoGuide

Copenhagen, Denmark, 13 May 2026 – FluoGuide A/S ("FluoGuide" or the "Company") is inviting investors to an event on Tuesday, June 2, 2026, where participants will get a close-up look at the...

<div class="mfn-preamble"><p><strong>Copenhagen, Denmark, 13 May 2026 – FluoGuide A/S ("FluoGuide" or the "Company") is inviting investors to an event on Tuesday, June 2, 2026, where participants will get a close-up look at the company’s technology and clinical applications through a live brain surgery simulation using FluoGuide’s drug candidate FG001.</strong></p></div><div class="mfn-body"><p>The attendees will have the opportunity to</p><ul><li>Do a live microscope-based simulation of brain surgery and experience the difference between surgery performed with and without FG001.</li><li>Meet Dr Jane Skjøth-Rasmussen, MD, PhD. neurosurgeon at Rigshospitalet, who leads the Danish clinical trials in brain tumors with FG001 and has performed the highest number of surgeries using FG001 to date.</li><li>Learn about the practical implications of FluoGuide’s: FDA Fast Track designation and IND (Investigational New Drug) clearance for the U.S. market.</li><li>Gain insight into the clinical results for FG001 and upcoming milestones in aggressive brain cancer and head &amp; neck cancer.</li></ul><p>Time and Location</p><ul><li>Date: Tuesday, June 2, 2026</li><li>Time: 16:30–18:00 CET</li><li>Location: Titanhus, Titangade 9–13, 2200 Copenhagen.</li></ul><p><strong>The invitation (in Danish is enclosed). Registration is required by follow this </strong><strong><a href="https://fluoguide.com/event/fluoguide-event/" rel="noopener">link</a></strong><strong> (https://fluoguide.com/event/fluoguide-event/)</strong></p></div><div class="mfn-footer mfn-contacts mfn-c60fb25dd154"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Morten Albrechtsen, CEO<br>FluoGuide A/S<br>Phone: +45 24 25 62 66<br>E-mail: ma@fluoguide.com</p></div><div class="mfn-footer mfn-about mfn-889f859209e1"><p><strong class="mfn-heading-1">About FluoGuide</strong><br>FluoGuide lights up cancer to maximize surgical outcomes in oncology. FluoGuide’s lead product, FG001, is designed to improve surgical precision by lighting up cancer intraoperatively. The improved precision has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision enhances the likelihood of complete cure and lower healthcare costs. FluoGuide has demonstrated that FG001 is both effective and well tolerated in several phase II clinical trials. The lead indications of FG001 are aggressive brain cancer (glioblastoma) and oral head and neck cancer. FluoGuide has entered partnerships with leading MedTech companies with the aim of accelerating development and commercialization. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.</p><p>For more information on FG001 or FluoGuide’s uPAR technology platform, please visit our home page www.fluoguide.com</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/0b38d6d0-54ca-4ca4-bf31-370c584ea94b/invitation-to-brain-surgery-simulation.pdf" rel="noopener">Invitation to brain surgery simulation</a><br><a href="https://storage.mfn.se/2803ddc5-e267-462b-ac80-7c46bd741f09/invitation-2-juni-2026-brain-surgery-simulation.pdf" rel="noopener">Invitation 2 Juni 2026 Brain Surgery Simulation</a></p></div>

Invitation to brain surgery simulation

Intervjuer i samband med Stockholm Corporate Finance 17:e Kapitalmarknadsdagar Life Science 2026

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Return on capital (ROE, ROI, ROIC, RONIC)

Finanslingo enkelt förklarat: EBIT, EBITA och EBITDA 

Saab

Bittium

W5 Solutions

Scandinavian Astor Group

MilDef Group

INVISIO

Argo Defence Group

European Defense Sector Outlook: Long-cycle rearmament drives fundamentals, but stretched valuations force selectivity